Patents by Inventor Alan X. Xiang
Alan X. Xiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952375Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: September 24, 2021Date of Patent: April 9, 2024Assignee: eFFECTOR Therapeutics Inc.Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
-
Publication number: 20230295179Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: May 26, 2023Publication date: September 21, 2023Inventors: Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan X. XIANG, Christian NILEWSKI, Theo MICHELS
-
Publication number: 20230108594Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: January 28, 2022Publication date: April 6, 2023Inventors: Samuel SPERRY, Alan X. XIANG, Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Mike SHAGHAFI, Theo Michels, Christian NILEWSKI, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan GRUBBS, Kaveri URKALAN, Takasuke MUKAIYAMA
-
Publication number: 20230071483Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: April 14, 2022Publication date: March 9, 2023Inventors: Justin T. ERNST, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan X. XIANG, Christian NILEWSKI, Theo MICHELS
-
Patent number: 11440917Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: February 28, 2020Date of Patent: September 13, 2022Assignee: EFFECTOR THERAPEUTICS, INC.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels
-
Publication number: 20220119387Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: September 24, 2021Publication date: April 21, 2022Inventors: Siegfried H. REICH, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
-
Patent number: 11286268Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: June 30, 2020Date of Patent: March 29, 2022Assignee: eFFECTOR Therapeutics, Inc.Inventors: Samuel Sperry, Alan X. Xiang, Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Mike Shaghafi, Theo Michels, Christian Nilewski, Chinh Viet Tran, Garrick Kenneth Packard, Alan Grubbs, Kaveri Urkalan, Takasuke Mukaiyama
-
Publication number: 20210338673Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.Type: ApplicationFiled: May 5, 2021Publication date: November 4, 2021Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. XIANG, Justin T. Ernst
-
Patent number: 11130757Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: October 23, 2019Date of Patent: September 28, 2021Assignee: eFFECTOR Therapeutics Inc.Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
-
Publication number: 20200339590Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: February 28, 2020Publication date: October 29, 2020Applicant: eFector Therapautics, Inc.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels
-
Patent number: 10793551Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, Y1, Y2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: October 17, 2018Date of Patent: October 6, 2020Assignee: eFFECTOR Therapeutics Inc.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Alan X. Xiang
-
Publication number: 20200131179Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: October 23, 2019Publication date: April 30, 2020Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Emst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
-
Patent number: 10577378Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: March 12, 2018Date of Patent: March 3, 2020Assignee: eFFECTOR Therapeutics, Inc.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels
-
Publication number: 20190209560Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.Type: ApplicationFiled: November 2, 2018Publication date: July 11, 2019Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst
-
Publication number: 20190119256Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, Y1, Y2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: October 17, 2018Publication date: April 25, 2019Applicant: eFFECTOR Therapeutics, Inc.Inventors: Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Alan X. XIANG
-
Publication number: 20180298017Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: March 12, 2018Publication date: October 18, 2018Applicant: eFFECTOR Therapeutics, Inc.Inventors: Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan X. XIANG, Christian NILEWSKI, Theo MICHELS
-
Patent number: 9957277Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: November 22, 2016Date of Patent: May 1, 2018Assignee: eFFECTOR Therapeutics, Inc.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels
-
Publication number: 20180085368Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.Type: ApplicationFiled: November 10, 2017Publication date: March 29, 2018Applicant: eFFECTOR Therapeutics, Inc.Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst
-
Patent number: 9814718Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.Type: GrantFiled: June 2, 2017Date of Patent: November 14, 2017Assignee: eFFECTOR THERAPEUTICS, INC.Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst
-
Publication number: 20170266185Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.Type: ApplicationFiled: June 2, 2017Publication date: September 21, 2017Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. ERNST